Navigation Links
Skin transplant offers new hope for vitiligo patients
Date:5/30/2012

DETROIT Henry Ford Hospital dermatologists say skin transplant surgery is safe and effective for restoring skin pigmentation caused by the skin disease vitligo.

In a first study of its kind in the United States, researchers followed 23 patients for up to six months after surgery and found that the treated area regained on average 43 percent of its natural skin color. In eight patients with localized vitiligo, the treated area regained on average 68 percent of its natural skin color.

The surgery involves using skin cells taken from healthy, normally pigmented areas of the body and transferring them to the damaged area of skin. It is performed under local anesthesia.

The study is published in the May edition of the Journal of the American Academy of Dermatology. It is available online at http://www.eblue.org/article/S0190-9622(11)00527-5/abstract.

"The results achieved in our study were of obvious significance to our patients," says Iltefat Hamzavi, M.D., a senior staff physician in Henry Ford's Department of Dermatology and the study's senior author and principal investigator. "We believe this new treatment option offers hope to patients of color and those with vitiligo on one side of the body or in one area of the body."

Vitiligo is a skin disease that causes the skin to lose color and develop white patches that vary in size and location. It affects about 1 in every 200 people in the United States, and is more noticeable in people with darker skin. Standard treatments include light therapy and topical medications.

Vitiligo develops when cells called melanocytes are killed by the body's immune system, causing the area of skin to turn white because the cells no longer make pigment. While there is no cure, vitiligo can be treated and managed with light therapy, creams and topical medications.

The surgery is known as melanocyte-keratinocyte transplantation, or MKTP, and is performed in Europe, Asia and the Middle East. It was performed at Henry Ford using the same technique developed by MKTP pioneer Sanjeev Mulekar, M.D., of the National Vitiligo Center in Saudi Arabia. Henry Ford is the first to perform MKTP in North America.

In Henry Ford's study, 28 patients underwent surgery and ranged in age from 18 to 60. A total of 36 MKTP procedures were performed and researchers analyzed the outcomes of 29 of them. The procedure lasted 30 minutes to two hours and patients returned home the same day.

Of the 28 surgery patients, 23 were followed for up to six months after surgery. Eighteen patients received one treatment, four patients received two and one patient received three. The ethnicity of patients was Caucasian, South Asian, African American and Hispanic.

During MKTP, melanocyte cells, which produce pigment in the skin, hair and eyes, are harvested from an area of healthy skin and separated to make a skin cell mixture. This mixture then is applied to the treatment area and covered with a specially developed adhesive biologic dressing.

Treated areas included the hands, arms, legs, feet, face and stomach. The average size of the treated area during each procedure was 46 cm2, or roughly the size of a credit card.


'/>"/>

Contact: David Olejarz
David.Olejarz@hfhs.org
313-874-4094
Henry Ford Health System
Source:Eurekalert  

Related medicine news :

1. New drug for kidney transplant recipients effective in humans
2. WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday
3. Spanish Only, Please: Special Latino Clinic Launched For Potential Abdominal Transplant Patients
4. WellPoint/Blue Cross Liver Transplant Denial Trial Begins Today, Illustrates Need for Toughening of White House Reform Plan
5. Newer cornea transplant surgery shows short- and long-term promise
6. Cristophe Salon in Beverly Hills Teams Up with Mad Men Actor to Help Raise Money for His 17-Year-Old Cousins Heart Transplant
7. Two Babies Born a Year Apart After Ovary Transplant
8. Wounded Soldier Who Received Historic Cell Transplant Gets Standing Ovation at Diabetes Research Institute Benefit
9. Internal Anthem Blue Cross/WellPoint Document: Only Patients Who Push Back Get Covered Out of State Liver Transplants
10. Drug dramatically reduces nausea and vomiting in bone marrow transplant patients
11. Kidney Patients From Across South Carolina Visit State Capitol to Encourage Policies that Improve Patient Access to Life-Saving Dialysis and Transplant Care
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Skin transplant offers new hope for vitiligo patients
(Date:3/28/2017)... ... March 28, 2017 , ... Nurse practitioners and physician assistants ... increases in the healthcare workforce, according to a survey recently released by ... and candidate leads to healthcare employers of physicians and advanced practice clinicians. , ...
(Date:3/28/2017)... ... ... and fungi are probably not the first ingredients that come to mind when thinking about ... your diet can actually improve health outcomes. And the good news is they may be ... new peer-reviewed paper led by Maria Marco, Ph.D. , University of California, ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... patients for clear braces. People who want straight teeth without the extensive time ... in Clearwater, FL, without acquiring a referral. A custom-designed series of virtually ...
(Date:3/27/2017)... ... 2017 , ... New patients who want to experience the benefits of ... them placed by Dr. Manju Kejriwal, with or without a referral. Dr. Kejriwal is ... accuracy of each dental implant placement. The i-CAT CBCT system captures the shapes of ...
(Date:3/27/2017)... UK (PRWEB) , ... March 27, 2017 , ... ... and ability to gain site attention and engagement over the household brands of ... webinar will discuss how partnering with the right outsourcing payments provider ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  Allergan plc, ... Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company ... therapies based upon tetracycline chemistry, announced that two ... treatment of moderate to severe acne met their ... once-daily, oral, narrow spectrum tetracycline-derived antibiotic with anti-inflammatory ...
(Date:3/27/2017)... , March 27, 2017 Cota ... for value-based precision medicine, today announced the ... Novartis Pharmaceuticals Corporation to help improve clinical ... As part of this agreement, ... collaboration entered into January 2016, teams from ...
(Date:3/27/2017)... SAN DIEGO , March 27, 2017 ... biopharmaceutical company focused on developing novel, small molecule drugs across ... Company,s President and Chief Executive Officer, will present a corporate ... April 4 at 3:40pm ET.  The conference will take place ... in New York , NY.  ...
Breaking Medicine Technology: